There was bad news almost across the board for the biotech sector in the third quarter. Amounts raised via initial public offerings and venture capital firms were down from first quarter highs by 46% and 41%, respectively. Overall, biotech financing is down by about a third from the same quarter in the previous year. The BioCentury and Nasdaq biotech stock market indices diverged this quarter, probably indicating that the biggest biotechs are still doing well whereas smaller ones are suffering.
Credit: Source: Multex, BioCentury, Swiss Exchange
Credit: Source: BioCentury
Credit: Source: BioCentury, Burrill & Company
Credit: Source: BioCentury
Rights and permissions
About this article
Cite this article
Lawrence, S. Biotech in decline in Q3. Nat Biotechnol 22, 1342 (2004). https://doi.org/10.1038/nbt1104-1342
Issue Date:
DOI: https://doi.org/10.1038/nbt1104-1342
